MX2017002674A - Anticuerpos terapeuticos que se unen a oprf y opri. - Google Patents

Anticuerpos terapeuticos que se unen a oprf y opri.

Info

Publication number
MX2017002674A
MX2017002674A MX2017002674A MX2017002674A MX2017002674A MX 2017002674 A MX2017002674 A MX 2017002674A MX 2017002674 A MX2017002674 A MX 2017002674A MX 2017002674 A MX2017002674 A MX 2017002674A MX 2017002674 A MX2017002674 A MX 2017002674A
Authority
MX
Mexico
Prior art keywords
antibodies
oprl
oprf
derivatives
polypeptides
Prior art date
Application number
MX2017002674A
Other languages
English (en)
Inventor
Zhou Heyue
f kaufmann Gunnar
Original Assignee
Sorrento Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorrento Therapeutics Inc filed Critical Sorrento Therapeutics Inc
Publication of MX2017002674A publication Critical patent/MX2017002674A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se divulgan composiciones y métodos relacionados con anticuerpos anti-OprF y anti-Oprl o derivados de los mismos. Más específicamente, se divulgan anticuerpos completamente humanos que se unen a OprF y OprI, fragmentos y derivados de unión de OprF y OprI de dichos anticuerpos, y polipéptidos que se unen a OprF y Oprl que comprenden dichos fragmentos. Además, se divulgan ácidos nucleicos que codifican dichos anticuerpos, fragmentos y derivados de anticuerpo y polipéptidos, células que comprenden dichos polinucleótidos, métodos de preparación de dichos anticuerpos, fragmentos y derivados de anticuerpo y polipéptidos, y métodos de uso de dichos anticuerpos, fragmentos y derivados de anticuerpo y polipéptidos, que incluyen métodos de tratamiento o diagnóstico de sujetos que tienen infecciones de Pseudomonas aeruginosa. Se divulga un método de tratamiento o prevención de infecciones de Pseudomonas aeruginosa, en donde la enfermedad se selecciona del grupo que consiste en quemaduras, infecciones de sitio quirúrgico, úlceras del pie diabético, heridas infectadas y fibrosis quística.
MX2017002674A 2014-08-29 2015-08-28 Anticuerpos terapeuticos que se unen a oprf y opri. MX2017002674A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462044107P 2014-08-29 2014-08-29
PCT/US2015/047576 WO2016033547A1 (en) 2014-08-29 2015-08-28 Antibody therapeutics that bind oprf and oprl

Publications (1)

Publication Number Publication Date
MX2017002674A true MX2017002674A (es) 2017-09-19

Family

ID=55400714

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017002674A MX2017002674A (es) 2014-08-29 2015-08-28 Anticuerpos terapeuticos que se unen a oprf y opri.

Country Status (16)

Country Link
US (1) US9879069B2 (es)
EP (1) EP3185897A4 (es)
JP (1) JP2017526686A (es)
KR (1) KR20170068456A (es)
CN (1) CN107073096A (es)
AU (1) AU2015308625A1 (es)
BR (1) BR112017003983A2 (es)
CA (1) CA2959165A1 (es)
EA (1) EA201790489A1 (es)
IL (1) IL250755A0 (es)
MA (1) MA40528A (es)
MX (1) MX2017002674A (es)
PH (1) PH12017500368A1 (es)
SG (1) SG11201701529YA (es)
WO (1) WO2016033547A1 (es)
ZA (1) ZA201701915B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114874322A (zh) * 2016-03-10 2022-08-09 维埃拉生物股份有限公司 Ilt7结合分子及其使用方法
WO2017163049A1 (en) * 2016-03-21 2017-09-28 Kymab Limited Anti-malarial antibodies that bind circumsporozoite protein
US11066464B2 (en) 2016-03-21 2021-07-20 Kymab Limited Anti-malarial antibodies that bind circumsporozoite protein
US11485792B2 (en) 2016-06-06 2022-11-01 Polytherics Limited Antibodies, uses thereof and conjugates thereof
WO2019192432A1 (zh) * 2018-04-02 2019-10-10 上海博威生物医药有限公司 结合淋巴细胞活化基因-3(lag-3)的抗体及其用途
FR3099160B1 (fr) * 2019-07-23 2022-05-06 Univ Grenoble Alpes Anticorps dirigé contre la protéine oprf depseudomonas aeruginosa, son utilisation en tant que médicament et composition pharmaceutique le contenant

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0717106B1 (en) * 1994-12-16 2000-03-15 Chiron Behring Gmbh & Co. Immunogenic hybrid protein OprF-Oprl derived from Pseudomonas aeruginosa membrane proteins
AU2009313551B2 (en) 2008-11-07 2015-12-17 Fabrus Llc Anti-DLL4 antibodies and uses thereof
JP5893640B2 (ja) * 2010-12-23 2016-03-23 ファルネファ オーストリア ゲーエムベーハー Ｏｐｒｆ／ｉ試薬と入院および他の患者におけるその利用
JP5976686B2 (ja) * 2011-02-23 2016-08-24 アルツケム アクチェンゲゼルシャフト エポキシ樹脂のための新規な硬化剤
EP3553086A1 (en) 2012-05-31 2019-10-16 Sorrento Therapeutics Inc. Antigen binding proteins that bind pd-l1

Also Published As

Publication number Publication date
US9879069B2 (en) 2018-01-30
US20160060326A1 (en) 2016-03-03
AU2015308625A1 (en) 2017-04-20
MA40528A (fr) 2017-07-05
BR112017003983A2 (pt) 2018-02-14
EA201790489A1 (ru) 2017-08-31
PH12017500368A1 (en) 2017-07-10
SG11201701529YA (en) 2017-03-30
WO2016033547A8 (en) 2017-04-06
ZA201701915B (en) 2018-05-30
EP3185897A1 (en) 2017-07-05
KR20170068456A (ko) 2017-06-19
CN107073096A (zh) 2017-08-18
WO2016033547A1 (en) 2016-03-03
JP2017526686A (ja) 2017-09-14
EP3185897A4 (en) 2018-05-02
IL250755A0 (en) 2017-04-30
CA2959165A1 (en) 2016-03-03

Similar Documents

Publication Publication Date Title
PH12017500368A1 (en) Antibody therapeutics that bind oprf and opri
EA201892482A1 (ru) Соединения, модулирующие fxr (nr1h4)
EA201892480A1 (ru) Соединения, модулирующие fxr (nr1h4)
MX2017011329A (es) Productos terapeuticos de anticuerpos que se enlazan a cd47.
EA201791017A1 (ru) Гидроксисодержащие соединения, модулирующие fxr (nr1h4)
WO2017015560A3 (en) Antibody therapeutics that bind lag3
EA201790377A1 (ru) Антитела к глюкагону и их применения
CY1124412T1 (el) Aνti-dkk-1 αντισωματα
WO2016144803A8 (en) Antibody therapeutics that bind tim3
EA201890169A1 (ru) Тау-связывающие антитела
EA201890453A1 (ru) Анти-angptl8 антитела и их применение
CO6640289A2 (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
WO2016164669A3 (en) Antibody therapeutics that bind cd38
EA201891732A1 (ru) Биспецифичные связывающие белки для pd-l1 и kdr
WO2017081211A3 (en) Antigen-binding polypeptides directed against cd38
EA202191566A1 (ru) Соединения, модулирующие fxr (nr1h4)
EA201892774A1 (ru) Антитела
WO2014200898A3 (en) Cmv neutralizing antigen binding proteins
EA201171043A1 (ru) Композиции и способы длительной терапии с применением аминопиридинов
EA201890225A1 (ru) Слитые белки, которые связываются с fc рецепторами человека
EA201791898A1 (ru) Новые антитела, связывающиеся с tfpi, и содержащая их композиция
EA201500270A1 (ru) Фторметилзамещенные пирролкарбоксамиды
EA202090014A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
NZ721015A (en) Mutant fragments of ospa and methods and uses relating thereto
PH12017500156A1 (en) Angiopoietin-like 4 antibodies and methods of use